Notably, there was no difference in the use of Dipeptyl Peptidase-IV Inhibitors (DPP-4) inhibitor medication (1.9% in the cholangitis group vs. 0.6% in the non-cholangitis group, p = 0.14). The gene discussed is DPP4; the disease is cholangitis.